Extended Data Figure 10: HPDL is important for a subset of PDAC tumours.
From: The polar oxy-metabolome reveals the 4-hydroxymandelate CoQ10 synthesis pathway
a, Orthotopic pancreatic tumour weight from the indicated MIAPACA2 xenografts. b, c, Tumour images (b) and weights (c) from a second experiment of orthotopic pancreatic tumour xenografts from MIAPACA2 cells expressing control or HPDL sgRNA with coHPDL WT or catalytically inactive mutant after 6 weeks post-injection. The first experiment set is found in a. d–g, Tumour images (d, –f) and weight (e, g) of orthotopic (d, e) or subcutaneous (f, g) pancreatic tumour xenograft of PATU-8902 cells expressing control or HPDL sgRNA after 5 weeks post-injection. h, i, Representative (h) and quantification (i) of H&E and immunohistochemistry for cleaved caspase 3 (CC3), phospho-histone H3 (p-HH3), and the death to proliferation ratio (CC3:p-HH3) from MIAPACA2 tumours from a. j, Overall and progression-free survival of HPDL high (n = 44) and low (n = 96) expressing PDAC tumours from the TCGA dataset. “n,” and each point represents the number of biologically independent experiments for each group and condition. Survival curve (j) was compared using the two-sided Log-rank (Mantel-Cox) test. Graphs (median ± max/min (a, c, e, g, i)) were compared by two-tailed Mann Whitney test (e, g), one-way ANOVA (a, c, i), followed by Holm-Sidak post hoc test (*P < 0.05, ^P < 0.01, %P < 0.005, #P < 0.0001).
